Day 3 Program

Rapid Fire 7

Day 3: December 11, 2025

1:00 PM–2:00 PM CST

Stars at Night 1-2

Session Details

Oral presentations of high impact clinical trials and translation science 

RF7-03

Updated results and an exploratory analysis of ESR1m circulating tumor DNA (ctDNA) dynamics from SERENA-6, a phase 3 trial of camizestrant (CAMI) + CDK4/6 inhibitor (CDK4/6i) for emergent ESR1 mutations (ESR1m) during first-line (1L) endocrine-based therapy and ahead of disease progression in patients (pts) with HR+/HER2- advanced breast cancer (ABC)

François-Clément Bidard, Institut Curie, Paris, France

RF7-04

Gedatolisib, a multi-target PI3K/AKT/mTOR (PAM) inhibitor, plus fulvestrant with or without palbociclib for second-line (2L) treatment of patients with HR+/HER2-/PIK3CA-wild type (WT) advanced breast cancer (ABC): updated results from the randomized, phase 3 VIKTORIA-1 trial

Barbara Pistilli, Gustave Roussy, Villejuif, France

RF7-05

Capivasertib plus fulvestrant in hormone receptor-positive (HR+) advanced breast cancer (ABC): exploratory ctDNA analyses from the Phase 3 CAPItello-291 trial

Nicholas C Turner, Royal Marsden Hospital, Institute of Cancer Research, London, United Kingdom

RF7-06

Primary results of Ambre, a randomized phase 3comparing mono-chemotherapy (ct) vs abemaciclib + endocrine therapy (et) in hr+/her2- advanced breast cancer (abc) with high visceral tumor burden

Véronique Dieras, Centre Eugène Marquis, Rennes, France

RF7-07

Adjuvant Palbociclib for ER+ Breast Cancer in the PALLAS Trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13): Post-Recurrence Treatment and Overall Survival

Angela DeMichele, University of Pennsylvania, Philadelphia, PA